99P Exploratory analysis of differential gene expression (DGE) and non-negative matrix factorisation (NMF) clustering in KATHERINE: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with HER2-positive residual invasive breast cancer after neoadjuvant treatment (NAT)

C Denkert,M Nowicka,M Basik,G Lewis,P.A Fasching,P Lucas,D Eiger,C.E Geyer,S Loibl,S De Haas,C Lambertini

doi:10.1016/j.esmoop.2023.101323

99P Exploratory analysis of differential gene expression (DGE) and non-negative matrix factorisation (NMF) clustering in KATHERINE: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with HER2-positive residual invasive breast cancer after neoadjuvant treatment (NAT)

C Denkert, M Nowicka + Show 9 more

Open Access

https://doi.org/10.1016/j.esmoop.2023.101323

Copy DOI

Journal: ESMO Open	Publication Date: May 1, 2023
License type: cc-by-nc-nd

Affiliation: UPMC Hillman Cancer Center, Roche (Switzerland), Philipps University of Marburg, Universitätsklinikum Erlangen, German Breast group, McGill University

#Adjuvant Trastuzumab Emtansine #Analysis Of Differential Gene Expression + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

99P Exploratory analysis of differential gene expression (DGE) and non-negative matrix factorisation (NMF) clustering in KATHERINE: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with HER2-positive residual invasive breast cancer after neoadjuvant treatment (NAT)

Full Text